Promoter holding
64.27%
MP
Medoz Pharmaceuticals Private Limited - Due diligence report
A 360° intelligence report on Medoz Pharmaceutical: trust score, financial health, credit view, compliance, directors, growth and distress s…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Medoz Pharmaceutical — 360° Intelligence Report
Generated from MCA filings & public records92/100
Trust Score
Low Risk
Medoz Pharmaceutical is assessed as Low Risk with a Trust Score of 92/100. Medoz Pharmaceutical is an active private limited indian non-government company incorporated in 2000, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Jul 2026 from the latest processed filings. Medoz Pharmaceuticals Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
92/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
55/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
80/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 55/100 Moderate
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 4 open (7.26 cr) · 2 satisfied (4.98 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 2 | 48.0 cr |
| Hdfc Bank Limited | 1 | 48.0 cr |
| State Bank Of Patiala | 1 | 48.0 cr |
| Director Of Industries Himachal Pradesh | 1 | 48.0 cr |
| Canara Bank | 1 | 48.0 cr |
Compliance Score: 86/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Litigation present in 2 court forum(s).
- 1 active GST registration(s).
Legal cases on record (2)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| PARMAR RAMESHKUMAR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAKESH JAMBUPRASAD AGRAWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: RAKESH JAMBUPRASAD AGRAWAL (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 80 · Distress 90
Growth signals & trust indicators
Steady revenue growth: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
Operating for 26+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
4 open charge(s) registered - assets are encumbered.
2 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence89/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment75/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 4 open charge(s) of 7.26 cr already registered.
- Compliance record supports lending.
Investor view88/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 4 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
24 Jul 2024
Charge created
Others - 19.58 Lakh
22 Apr 2022
Charge satisfied
Hdfc Bank Limited
09 Mar 2021
Charge created
Hdfc Bank Limited - 3.39 cr
02 Nov 2020
Charge created
Canara Bank - 17.00 Lakh
16 Dec 2019
Director ceased
ANIL KUMAR AGARWAL
13 Dec 2019
Charge satisfied
State Bank Of Patiala
25 Sep 2019
Charge created
Others - 6.60 cr
18 Sep 2019
Director appointed
PARMAR RAMESHKUMAR (Director)
10 Apr 2019
Director ceased
JAMBUKUMAR JAIN
Director ceased
NANDKISHORE MAHESHWARI
30 Sep 2013
Director ceased
RAKESH JAMBUPRASAD AGRAWAL
21 Feb 2011
Charge created
Director Of Industries Himachal Pradesh - 30.00 Lakh
08 Mar 2006
Charge created
State Bank Of Patiala - 1.59 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - manageable leverage.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
| Company | CIN | Location |
|---|---|---|
| Francis Remedies (India) Private Limited | U24231DL2006PTC146931 | Delhi, Delhi, India |
| Phaedrus Life Science Private Limited | U24230GJ2014PTC081003 | Ahmedabad, Gujarat, India |
| Ridge Formulations Private Limited | U24110HP2017PTC006780 | Solan, Himachal Pradesh, India |
| Sunij Pharma Private Limited | U24231GJ2000PTC038712 | Ahmedabad, Gujarat, India |
| Apco Dye Chem Private Limited | U24112UP1989PTC010945 | Uttar Pradesh, Uttar Pradesh, India |
| Shalman Pharmaceuticals Private Limited | U24231GJ1994PTC022380 | Baroda, Gujarat, India |
| Apco Pharma Limited | U74899DL1994PLC059098 | New Delhi, Delhi, India |
| Bills Biotech | U24239GJ2006PTC048975 | Ahmedabad, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Medoz Pharmaceutical before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Medoz Pharmaceutical: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 55/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 80/100, margin trends, ownership structure and peer set for Medoz Pharmaceutical - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 92/100, distress signals and MSME payment-delay disclosures - know whether Medoz Pharmaceutical pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Medoz Pharmaceutical - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Medoz Pharmaceutical an active company?
Medoz Pharmaceutical has MCA status “Active” with a compliance score of 86/100 (Low Risk).
Is Medoz Pharmaceutical financially healthy?
Medoz Pharmaceutical has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Medoz Pharmaceutical?
Its overall Trust Score is 92/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Medoz Pharmaceutical?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.
Does Medoz Pharmaceutical have loans or charges against its assets?
4 open charge(s) are registered against its assets, and 2 earlier charge(s) stand satisfied.
Is Medoz Pharmaceutical up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).
Is it risky to lend to Medoz Pharmaceutical?
Its Credit Risk Score is 55/100 (Moderate). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
